CustomerInsights.AI (CIAI) is excited to announce a strategic collaboration with Ikigai Labs to explore the potential of pharma-specific enterprise grade GenAI for structured data sets. This collaboration aims to address critical use-cases in the pharmaceutical industry, including integrated sales forecasting, call routing, resource planning, pharmacy fraud detection, and automated data matching at scale.
The partnership will connect CIAI’s ciPARTHENON™ Commercial Analytics Cloud, which offers 40+ out-of-the-box apps, with IKIGAI’s state-of-the-art large graphical model (LGM) platform. The collaboration will advance highly scalable AI solutions to meet the unique challenges of the pharmaceutical sector.
Also Read: Rezo Therapeutics Appoints Cristiana Guiducci, Ph.D., as Chief Scientific Officer
Abhay Jajoo, CEO of CustomerInsights.AI, said, “Teaming up with Ikigai unlocks endless possibilities. Together, through purpose-built AI apps, we will support the Life Sciences data and analytics market, efficiently and effectively, driving innovation and meaningful change. Gen AI for structured data will be a game changer for Pharma due to the availability of large-scale syndicated datasets in this Industry that are waiting to be explored”
Kamal Ahluwalia, President of IKIGAI, added, “Partnering with CIAI will advance our mission to unlock the value of tabular and time series data for industry. Our AI securely learns, uncovers, and explains patterns across only our customer’s data, making it ideal for enterprise use cases. We’re already driving outcomes in demand forecasting, inventory optimization, and workforce planning. With CustomerInsights.AI we will unlock cost savings, efficiencies, and competitive advantage achieved by connecting the right data and actions at the right time, unlocking tremendous value for patients and healthcare providers.”
The collaboration between CustomerInsights.AI and Ikigai Labs reflects their commitment to leveraging the latest technology to develop innovative AI solutions for the pharmaceutical industry. The exploratory phase will engage pharmaceutical leaders in collaborative projects focused on operational excellence and impactful results.
Source: PRNewswire
